No Data
No Data
HKEX Live | Concord Medical Bio-B (09966) fell more than 7%, company's overseas expansion hindered due to the failure of core product's clinical trial in foreign markets.
Zhixun Finance APP has learned that Koning Jieyi Pharmaceuticals-B (09966) fell more than 7%. As of the press release, it fell 7.23% to HKD 2.18, with a turnover of HKD 7.6199 million. Recently, Koning Jieyi Pharmaceuticals' partner TRACON in the United States announced that due to the failure of Enwolimumab to achieve the primary endpoint in clinical trials, further development will be terminated. This means that Koning Jieyi's only commercialized product, Enwolimumab's first indication, has temporarily failed overseas. Previously in 2019, Koning Jieyi Pharmaceuticals reached a collaboration agreement with TRACON in the United States, which was responsible for Tracon company.
Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products
Hong Kong Stock Market Movement| Concorde Pharmacy-B (09966) soared by 19%, clinical research on the treatment of late-stage solid tumors showed good tolerance
Zhixun Finance learned from the APP that Kangning Jerry Pharmaceuticals B (09966) surged 19%. As of press time, it rose 19.08% to HK$3.02, with a turnover of HK$87.057 million. On the news side, Kangning Jerry Pharmaceuticals recently announced that the Phase I clinical study data of its new HER2-targeting bispecific antibody conjugate (ADC) JSKN003 for HER2-expressing solid tumors in China will be first released at the 2024 ASCO Annual Meeting. The research conclusion shows that JSKN003 has good tolerability and in patients with advanced/metastatic solid tumors who have previously undergone multiple lines of systemic treatment.
China's clinical research data for the Kangningjeri HER2 bispecific antibody drug JSKN003 was first presented at the 2024 ASCO Annual Meeting.
The Phase I clinical study results of JSKN003-102 were reported at this year's ASCO Annual Meeting. JSKN003 has good tolerability and controllable safety in advanced/metastatic solid tumor patients receiving previous multi-line system treatments, and has shown encouraging anti-tumor activity during the dose escalation period. Suzhou, June 3, 2024 / PRNewswire/ -- Concorde Jerry Biopharmaceuticals (stock code: 9966.HK) announced the Phase I clinical research data (study number: JSKN003) of HER2 bispecific antibody drug JSKN003 for the treatment of HER2-expressing solid tumors in China.
Alphamab Presents Results of Phase 1/2 China Trial for Tumor Drug in US Oncology Meeting
Alphamab Oncology (HKG:9966) presented the results of a phase 1/2 clinical study of its JSKN003 drug for Chinese patients with advanced solid tumors at the American Society of Clinical Oncology meetin
Corning Jerry Pharmaceutical-B (09966.HK): The latest findings of the JSKN003 Phase I/II clinical study on advanced solid tumors presented at the 2024 ASCO Annual Meeting
On June 3, GLONGHUI | Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 phase I/ II clinical study (study number: JSKN003-102) (“JSKN003-102”) for patients with advanced solid tumors were announced during the 2024 ASCO Annual Meeting poster presentation (abstract number: 3031; poster number: 176), and the results of this study were also published on the company's website.
No Data